查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1957515

2026年全球非病毒基因递送技术市场报告

Non-Viral Gene Delivery Technologies Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，非病毒基因转殖技术的市场规模迅速扩张。预计该市场规模将从2025年的45.7亿美元成长到2026年的52.8亿美元，复合年增长率（CAGR）为15.5%。过去几年成长要素包括：对病毒载体递送方法的依赖、非病毒转染试剂获取困难、基因治疗研究日益增长的兴趣、质体DNA和mRNA递送试剂盒使用量的增加，以及电穿孔和物理递送技术的应用。

预计未来几年非病毒基因递送技术市场将快速成长，到2030年将达到92.6亿美元，复合年增长率（CAGR）为15.1%。预测期内的成长要素包括：先进脂质和聚合物奈米颗粒的开发、预配方奈米颗粒技术的扩展、对基因编辑和RNA干扰（RNAi）疗法的投资增加、对个人化基因治疗解决方案的需求不断增长，以及高通量和自动化递送平台的整合。预测期内的关键趋势包括：基于脂质和聚合物的非病毒递送系统应用日益广泛、CRISPR和Cas9基因编辑应用增长、对RNAi和DNA疫苗递送平台的需求增加、体外和体内基因治疗研究的扩展，以及细胞特异性和靶向性基因递送试剂的开发。

个人化医疗需求的不断增长预计将加速非病毒基因递送技术市场的发展。个人化医疗是一种根据个人的基因特征、生活方式和环境来优化预防、诊断和治疗的医疗模式。这种需求的成长源自于基因组分析技术的进步，该技术能够为每位患者提供精准诊断、个人化治疗和最佳治疗效果。随着人们对个人化医疗的兴趣日益浓厚，非病毒基因递送技术也越来越受到关注，因为它可以安全灵活地导入患者特异性治疗基因，同时避免病毒载体带来的风险。例如，根据美国非营利组织「个人化医疗联盟」（Coalition for Personalized Medicine）于2024年2月发布的报告，美国食品药物管理局（FDA）在2023年核准了16种针对罕见疾病的新型个人化治疗方法，高于2022年的6种。因此，个人化医疗需求的不断增长正在推动非病毒基因递送技术市场的发展。

非病毒基因递送市场的主要企业正在推进非病毒基因治疗平台等最尖端科技，以提高基因治疗的安全性和疗效。非病毒基因治疗平台无需使用病毒即可将治疗性基因和核酸导入细胞，从而实现针对多种疾病的精准可控递送，并最大限度地降低免疫反应和风险。例如，2023年10月，专注于基因治疗的美国生物技术公司Generation Bio宣布推出免疫抑制性DNA（iqDNA）。这种改良版的封闭式DNA（ceDNA）采用脂质奈米颗粒（LNP）进行递送，在小鼠和非人灵长类动物中产生的细胞激素谱和抗性与修饰的mRNA相似，从而逃避免疫系统的辨识。由于耐受性更佳，Generation Bio已将iqDNA作为其所有项目（包括其旗舰A型血友病A治疗项目）的核心DNA有效载荷。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球非病毒基因递送技术市场：吸引力评分及分析
  • 成长潜力分析、竞争评估、策略适宜性评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 数位化、云端运算、巨量资料、网路安全
    • 工业4.0和智慧製造
    • 人工智慧（AI）和自主人工智慧
    • 物联网、智慧基础设施、互联生态系统
  • 主要趋势
    • 基于脂质和聚合物的非病毒递送系统的扩展
    • CRISPR和Cas9基因编辑技术的应用范围不断扩大。
    • 对RNAi和DNA疫苗递送平台的需求不断增长
    • 扩大体外和体外基因治疗的研究
    • 细胞特异性和定向基因递送试剂的开发

第五章 终端用户产业市场分析

  • 生技公司
  • 生物製药公司
  • 研究机构
  • 大学和研究机构
  • 受託研究机构（CRO）

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球非病毒基因递送技术市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球非病毒基因递送技术市场规模、比较及成长率分析
  • 全球非病毒基因递送技术市场表现：规模与成长，2020-2025年
  • 全球非病毒基因递送技术市场预测：规模与成长，2025-2030年，2035年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 副产品
  • 试剂和试剂盒、输送装置和预配製奈米颗粒。
  • 送货
  • 体外、体内、离体
  • 透过技术
  • 电穿孔、脂质体转染、聚合物转染、物理方法（显微注射、基因枪）、奈米颗粒
  • 透过使用
  • 基因疗法、去氧核糖核酸(DNA) 疫苗、核糖核酸干扰 (RNAi)、成簇规律间隔短丛集重复序列 (CRISPR) 或 Cas9 基因编辑、蛋白质表达
  • 按最终用途
  • 生物技术和生物製药公司、研究机构和学术机构以及其他最终用户
  • 按类型细分：试剂和试剂盒
  • 转染试剂、质体去氧核糖核酸（DNA）试剂盒、信使核糖核酸（RNA）递送试剂盒、小干扰核糖核酸（RNA）递送试剂盒、成簇规律间隔短丛集重复序列相关蛋白（CRISPR）试剂、细胞特异性递送试剂
  • 按类型细分：输送装置
  • 电穿孔系统、显微注射系统、基因枪或生物标靶递送装置、超音波递送装置、动态基因递送系统
  • 按类型细分：预製奈米颗粒
  • 脂质奈米颗粒、聚合物奈米颗粒、金奈米颗粒、树状聚合物聚合物奈米颗粒、奈米碳管颗粒、无机化合物奈米颗粒

第十章 区域与国别分析

  • 全球非病毒基因递送技术市场：按地区划分，实际结果与预测，2020-2025年、2025-2030年预测、2035年预测
  • 全球非病毒基因递送技术市场：按国家/地区划分，实际结果和预测，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 非病毒基因递送技术市场：竞争格局及市场占有率（2024年）
  • 非病毒基因递送技术市场：公司评估矩阵
  • 非病毒基因递送技术市场：公司概况
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Evonik Industries AG
    • Moderna Inc.

第37章 其他大型企业和创新企业

  • Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

第38章：全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年非病毒基因递送科技市场：提供新机会的国家
  • 2030年非病毒基因递送技术市场：充满新机会的细分领域
  • 2030年非病毒基因递送技术市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第41章附录

简介目录
Product Code: PH4MNVGD01_G26Q1

Non-viral gene delivery technologies are methods for transferring genetic material into cells without using viruses as carriers. These technologies reduce safety risks and immune responses associated with viral vectors while enabling precise and controlled gene delivery. Their primary purpose is to modify or regulate gene expression for applications such as treating genetic diseases and advancing cell-based therapies.

The main product types of non-viral gene delivery technologies include reagents and kits, delivery devices, and pre-formulated nanoparticles. Reagents and kits are ready-to-use chemical formulations designed to introduce genetic material into cells without viral involvement. Delivery can occur through various modes, including in vitro, in vivo, and ex vivo, using technologies such as electroporation, lipid-based transfection, polymer-based transfection, physical methods (microinjection and gene gun), and nanoparticle-mediated delivery. These technologies are applied in multiple areas, including gene therapy, DNA vaccines, RNA interference (RNAi), CRISPR/Cas9 gene editing, and protein expression. Key end users include biotechnology and biopharmaceutical companies, research and academic institutes, and other organizations involved in genetic research and therapeutics.

Tariffs have impacted the non-viral gene delivery technologies market by increasing the cost of imported reagents, nanoparticles, and delivery devices, affecting both research and clinical applications. Segments like pre-formulated nanoparticles and advanced delivery devices are most affected, particularly in North America and Europe where imports constitute a significant share. While tariffs have raised operational costs and slowed adoption, they have also encouraged domestic manufacturing, investment in local R&D, and innovation in cost-effective gene delivery technologies.

The non-viral gene delivery technologies market research report is one of a series of new reports from The Business Research Company that provides non-viral gene delivery technologies market statistics, including non-viral gene delivery technologies industry global market size, regional shares, competitors with a non-viral gene delivery technologies market share, detailed non-viral gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral gene delivery technologies industry. This non-viral gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-viral gene delivery technologies market size has grown rapidly in recent years. It will grow from $4.57 billion in 2025 to $5.28 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to reliance on viral delivery methods, limited availability of non-viral transfection reagents, growing interest in gene therapy research, increasing use of plasmid dna and mrna delivery kits, adoption of electroporation and physical delivery techniques.

The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $9.26 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to development of advanced lipid and polymer nanoparticles, expansion of pre-formulated nanoparticle technologies, rising investment in gene editing and rnai therapeutics, increasing demand for personalized gene therapy solutions, integration of high-throughput and automated delivery platforms. Major trends in the forecast period include increasing adoption of lipid-based and polymer-based non-viral delivery systems, growth in crispr and cas9 gene editing applications, rising demand for rnai and dna vaccine delivery platforms, expansion of ex-vivo and in-vivo gene therapy research, development of cell-specific and targeted gene delivery reagents.

The surging need for personalized medicine is set to accelerate the non-viral gene delivery technologies market ahead. Personalized medicine tailors prevention, diagnosis, and therapy to an individual's distinct genetics, habits, and surroundings. This rising demand arises from progress in genomic sequencing, enabling precise diagnostics, customized treatments, and superior results suited to each patient. The heightened emphasis on personalized medicine spurs interest in non-viral gene delivery technologies, which provide secure, flexible ways to insert patient-specific therapeutic genes, avoiding viral vector hazards. For example, in February 2024, the Personalized Medicine Coalition, a US non-profit, noted that the FDA greenlit 16 new personalized therapies for rare diseases in 2023, up from 6 in 2022. Hence, the escalating demand for personalized medicine is propelling the non-viral gene delivery technologies market.

Key players in the non-viral gene delivery market are advancing cutting-edge options like non-viral genetic medicine platforms to enhance gene therapy safety and performance. A non-viral genetic medicine platform introduces therapeutic genes or nucleic acids into cells sans viruses, minimizing immune responses and risks, while allowing accurate, regulated delivery for diverse conditions. For instance, in October 2023, Generation Bio Co., a US biotech firm focused on genetic medicines, unveiled immune-quiet DNA (iqDNA). This enhanced version of their closed-ended DNA (ceDNA) dodges innate immune sensing, displaying cytokine profiles and tolerance akin to modified mRNA in mice and non-human primates via lipid nanoparticle (LNP) delivery. Thanks to iqDNA's enhanced tolerability, Generation Bio is adopting it as the core DNA payload across its programs, including the flagship hemophilia A initiative.

In September 2023, SOHM Inc., a US pharmaceutical company expert in generic and private-label drug production and distribution, purchased ABBIE Inc. for an undisclosed sum. This move bolsters SOHM's expertise in non-viral gene delivery technologies, equipping it to pioneer gene-editing innovations and grow its footprint in the expanding genetic therapeutics arena. ABBIE Inc. is a US-based gene-editing platform that transports genetic payloads through non-viral vectors.

Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

North America was the largest region in the non-viral gene delivery technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-viral gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-viral gene delivery technologies market consists of revenues earned by entities by providing services such as genetic material formulation, delivery system development, and transfection optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-viral gene delivery technologies market also includes sales of lipid nanoparticles, polymer-based carriers, electroporation devices, and microinjection systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Viral Gene Delivery Technologies Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses non-viral gene delivery technologies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-viral gene delivery technologies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The non-viral gene delivery technologies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product: Reagents And Kits; Delivery Devices; Pre-Formulated Nanoparticles
  • 2) By Delivery: In-Vitro; In-Vivo; Ex-Vivo
  • 3) By Technology: Electroporation; Lipid-Based Transfection; Polymer-Based Transfection; Physical Methods (Microinjection, Gene Gun); Nanoparticles
  • 4) By Application: Gene Therapy; Deoxyribonucleic Acid (DNA) Vaccines; Ribonucleic Acid Interference (RNAi); Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing; Protein Expression
  • 5) By End-Use: Biotechnology And Biopharmaceutical Companies; Research And Academic Institutes; Other End-Uses
  • Subsegments:
  • 1) By Reagents And Kits: Transfection Reagents; Plasmid Deoxyribonucleic Acid (DNA) Kits; Messenger Ribonucleic Acid (RNA) Delivery Kits; Small Interfering Ribonucleic Acid (RNA) Delivery Kits; Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents; Cell-Specific Delivery Reagents
  • 2) By Delivery Devices: Electroporation Systems; Microinjection Systems; Gene Guns Or Biolistic Delivery Devices; Ultrasound-Mediated Delivery Devices; Hydrodynamic Gene Delivery Systems
  • 3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles; Polymer-Based Nanoparticles; Gold-Based Nanoparticles; Dendrimer-Based Nanoparticles; Carbon Nanotube-Based Nanoparticles; Inorganic Compound-Based Nanoparticles
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Danaher Corporation; Merck KGaA; Evonik Industries AG; Moderna Inc.; Lonza Group AG; Bio-Rad Laboratories Inc.; Takara Bio Inc.; GenScript Biotech Corporation; ReCode Therapeutics Inc.; Altogen Biosystems Inc.; Generation Bio; Indee Labs Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Non-Viral Gene Delivery Technologies Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Non-Viral Gene Delivery Technologies Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Non-Viral Gene Delivery Technologies Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Non-Viral Gene Delivery Technologies Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Adoption Of Lipid-Based And Polymer-Based Non-Viral Delivery Systems
    • 4.2.2 Growth In Crispr And Cas9 Gene Editing Applications
    • 4.2.3 Rising Demand For Rnai And Dna Vaccine Delivery Platforms
    • 4.2.4 Expansion Of Ex-Vivo And In-Vivo Gene Therapy Research
    • 4.2.5 Development Of Cell-Specific And Targeted Gene Delivery Reagents

5. Non-Viral Gene Delivery Technologies Market Analysis Of End Use Industries

  • 5.1 Biotechnology Companies
  • 5.2 Biopharmaceutical Companies
  • 5.3 Research Institutes
  • 5.4 Academic And University Laboratories
  • 5.5 Contract Research Organizations (Cros)

6. Non-Viral Gene Delivery Technologies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Non-Viral Gene Delivery Technologies Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Non-Viral Gene Delivery Technologies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Non-Viral Gene Delivery Technologies Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Non-Viral Gene Delivery Technologies Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Non-Viral Gene Delivery Technologies Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Non-Viral Gene Delivery Technologies Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Non-Viral Gene Delivery Technologies Market Segmentation

  • 9.1. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles
  • 9.2. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Delivery, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • In-Vitro, In-Vivo, Ex-Vivo
  • 9.3. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles
  • 9.4. Global Non-Viral Gene Delivery Technologies Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression
  • 9.5. Global Non-Viral Gene Delivery Technologies Market, Segmentation By End-Use, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses
  • 9.6. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Reagents And Kits, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents
  • 9.7. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Delivery Devices, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems
  • 9.8. Global Non-Viral Gene Delivery Technologies Market, Sub-Segmentation Of Pre-Formulated Nanoparticles, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles

10. Non-Viral Gene Delivery Technologies Market Regional And Country Analysis

  • 10.1. Global Non-Viral Gene Delivery Technologies Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Non-Viral Gene Delivery Technologies Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Non-Viral Gene Delivery Technologies Market

  • 11.1. Asia-Pacific Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Non-Viral Gene Delivery Technologies Market

  • 12.1. China Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Non-Viral Gene Delivery Technologies Market

  • 13.1. India Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Non-Viral Gene Delivery Technologies Market

  • 14.1. Japan Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Non-Viral Gene Delivery Technologies Market

  • 15.1. Australia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Non-Viral Gene Delivery Technologies Market

  • 16.1. Indonesia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Non-Viral Gene Delivery Technologies Market

  • 17.1. South Korea Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Non-Viral Gene Delivery Technologies Market

  • 18.1. Taiwan Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Non-Viral Gene Delivery Technologies Market

  • 19.1. South East Asia Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Non-Viral Gene Delivery Technologies Market

  • 20.1. Western Europe Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Non-Viral Gene Delivery Technologies Market

  • 21.1. UK Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Non-Viral Gene Delivery Technologies Market

  • 22.1. Germany Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Non-Viral Gene Delivery Technologies Market

  • 23.1. France Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Non-Viral Gene Delivery Technologies Market

  • 24.1. Italy Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Non-Viral Gene Delivery Technologies Market

  • 25.1. Spain Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Non-Viral Gene Delivery Technologies Market

  • 26.1. Eastern Europe Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Non-Viral Gene Delivery Technologies Market

  • 27.1. Russia Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Non-Viral Gene Delivery Technologies Market

  • 28.1. North America Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Non-Viral Gene Delivery Technologies Market

  • 29.1. USA Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Non-Viral Gene Delivery Technologies Market

  • 30.1. Canada Non-Viral Gene Delivery Technologies Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Non-Viral Gene Delivery Technologies Market

  • 31.1. South America Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Non-Viral Gene Delivery Technologies Market

  • 32.1. Brazil Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Non-Viral Gene Delivery Technologies Market

  • 33.1. Middle East Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Non-Viral Gene Delivery Technologies Market

  • 34.1. Africa Non-Viral Gene Delivery Technologies Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Non-Viral Gene Delivery Technologies Market, Segmentation By Product, Segmentation By Delivery, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Non-Viral Gene Delivery Technologies Market Regulatory and Investment Landscape

36. Non-Viral Gene Delivery Technologies Market Competitive Landscape And Company Profiles

  • 36.1. Non-Viral Gene Delivery Technologies Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Non-Viral Gene Delivery Technologies Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Non-Viral Gene Delivery Technologies Market Company Profiles
    • 36.3.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Non-Viral Gene Delivery Technologies Market Other Major And Innovative Companies

  • Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

38. Global Non-Viral Gene Delivery Technologies Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Non-Viral Gene Delivery Technologies Market

40. Non-Viral Gene Delivery Technologies Market High Potential Countries, Segments and Strategies

  • 40.1 Non-Viral Gene Delivery Technologies Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Non-Viral Gene Delivery Technologies Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Non-Viral Gene Delivery Technologies Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer